For Patients

Therapies for your skin health

Biofrontera provides you with nanoemulsion technology for the treatment of actinic keratosis (AK). Actinic Keratosis is a potential precancer to squamous cell carcinoma, the second most common skin cancer.1 To learn more about photodynamic therapy (PDT) with the combination of red light and Ameluz® (aminolevulinic acid hydrochloride) gel, 10% for topical use, we have compiled important facts for you below and on the following pages.

 

Treating Actinic Keratosis

Ameluz® gel is a prescription drug approved by the FDA in combination with the red light BF-RhodoLED®. It is indicated for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.2 Ask your doctor about actinic keratoses and if Ameluz® and BF-RhodoLED® may be right for you.

 

1 Ameluz® Prescribing Information. For Ameluz® full prescribing information and BF-RhodoLED® user manual information please refer to: www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=650daa9f-aeec-49ce-95b9-5fa20b988afd

Important Safety Information

Active Ingredient (in each tube):  AMELUZ® (aminolevulinic acid hydrochloride) 

Purpose: Photosensitizing agent

Uses: AMELUZ® gel, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED® lamp, is used for lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp.

Warnings:

Do not use if you have a:

  • Known hypersensitivity to photoactive substances known as porphyrins.
  • Known hypersensitivity to soybeans
  • Known hypersensitivity to any component of AMELUZ®.

Ask your health care provider before use if you have:

  • Porphyria (hereditary disease that is characterized by abnormal production of a red blood pigment called heme).
  • Photodermatoses (skin conditions caused by or made worse by exposure to light or ultraviolet radiation).

When using this product:

  • Transient Amnestic Episodes: Photodynamic therapy may cause transient amnestic episodes (temporary loss of memory). If observed, the therapy must be stopped immediately. If observed after treatment, contact your health care provider.
  • Risk of Eye Injury: Patients and health care providers must wear protective eyewear while operating BF-RhodoLED®
  • Photosensitivity: Avoid sun exposure on the treated lesion sites and surrounding skin for approximately 48 hours following treatment
  • Risk of Bleeding: Special care should be taken to avoid bleeding during lesion preparation in patients with inherited or acquired coagulation disorders. Bleeding must be stopped before application of the gel.
  • Ophthalmic Adverse Reactions: Avoid applying AMELUZ® into the eyes. Wash eyes with water in case of accidental contact.
  • Mucous Membrane Irritation: Avoid direct contact of AMELUZ® with the mucous membranes. Wash with water in case of accidental contact.
  • Concomitant use of the following medications may increase the intensity of adverse reactions after light exposure related to photodynamic therapy: St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines.

Most common adverse reactions were:

  • skin reddening
  • scaling of the skin
  • pain/burning
  • scabbing
  • irritation
  • hardening
  • swelling
  • blistering
  • itching

Most side effects occurred during illumination or shortly afterwards, were generally of mild or moderate intensity, and lasted for 1 to 4 days in most cases; in some cases they persisted for 1 to 2 weeks or even longer.

Pregnancy Warning: There is no available data on AMELUZ® use in pregnant women to inform a drug associated risk.

Lactation Warning: There is no available data regarding the presence of the active ingredient (aminolevulinic acid hydrochloride) in human milk, or the effects of aminolevulinic acid hydrochloride on the breastfed infant or on milk production.

Pediatric Warning: Safety and effectiveness in pediatric patients below the age of 18 has not been established.

Geriatric Warning: No overall differences in safety or effectiveness were observed between older (65 years and older) and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Directions:

  • AMELUZ® is administered only by a health care provider.
  • AMELUZ® is for topical use only.
  • Photodynamic therapy with AMELUZ® involves preparation of lesions, application of the product, occlusion and illumination with BF-RhodoLED®
  • Retreat lesions that have not completely resolved 3 months after the initial treatment.

Inactive Ingredients: xanthan gum, soybean phosphatidylcholine, polysorbate 80, medium-chain triglycerides, isopropyl alcohol, dibasic sodium phosphate, monobasic sodium phosphate, propylene glycol, sodium benzoate and purified water.

Other Information: Store in a refrigerator, 2°C – 8°C (36°F – 46°F). Excursions permitted to 15°C – 30°C (59°F– 86°F). The risk information provided here is not comprehensive.

To learn more, talk about AMELUZ® with your health care provider. The FDA approved product labeling can be found at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=650daa9f-aeec-49ce-95b9-5fa20b988afd.

You are encouraged to report side effects of Ameluz®. Please contact Biofrontera Inc. at 1-844-829-7434 or FDA at 1-800-332-1088 or www.fda.gov/medwatch.